NASDAQ · VIR
Vir Biotechnology, Inc.
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
Loading market information…
NASDAQ · ARCT · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Arcturus Therapeutics Holdings Inc.’s forward annual dividend is $0.72 per share, paid monthly. The forward yield is 5.89% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Arcturus Therapeutics Holdings Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.68. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Arcturus Therapeutics Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 12, 2025 | -$0.52+67.09% vs estimate | $29.38M+25.82% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | -$1.11-236.36% vs estimate | $22.77M-43.01% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.26+62.86% vs estimate | $38.82M-15.48% vs estimate |
|---|
THE ANALYST VIEW
21 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $30.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$10.47+$0.15 (+1.45%)
Novavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.81% below the high.
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$4.28-$0.04 (-0.93%)
Arbutus Biopharma Corp’s quoted price sits in the lower half of its reported 52-week range, 21.47% below the high.
$5.71-$0.03 (-0.52%)
Valneva SE’s quoted price sits in the lower half of its reported 52-week range, 53.12% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$8.83+$0.03 (+0.34%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
